摘要
目的评价达比加群酯(Dabigatran Etexilate)和华法林(Warfarin)在非瓣膜性房颤(NVAF)抗凝治疗中的疗效及安全性。方法将64例NVAF患者随机分为达比加群酯组和华法林组,各32例,分别给予达比加群酯和华法林进行抗凝治疗。比较两组患者用药前和用药后2个月的凝血指标,以及栓塞和出血相关事件的发生情况。结果用药2个月后,两组患者的凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)、国际标准化比值(INR)均较用药前有不同程度的升高,差异有统计学意义(P<0.05);达比加群酯组患者轻微出血的发生率为6.25%,显著低于华法林组的15.62%(P<0.05)。结论达比加群酯预防NVAF患者栓塞和缺血性脑卒中发生的疗效与华法林相似,但达比加群酯的安全性更高,值得临床推广。
Objective To discuss the clinical effects and safety of Dabigatran and Warfarin in treating patients with nonvalvular atrial fibrillation（NVAF）. Methods 64 patients with NVAF were selected and randomly divided into the Dabigatran group and the Warfarin group, 32 cases in each group. The coagulation parameters of the two groups before treatment and 2 months after treatment were compared, as well as the occurrence of embolism and bleeding related events. Results The levels of PT, APTT, TT, FIB, INR had been increased in the two group after 2-month treatment（P 〈 0. 05）. The incidence rate of slight bleeding was 6. 25% in the Dabigatran group,which was obviously lower than 15.62% that in the Warfarin group（P 〈 0. 05 ）. Conclusion The efficacy of Dabigatran in the prevention of embolization and ischemic stroke in NVAF patients is similar to that of Warfarin, but dabigatran is more safe and worthy of clinical promotion.
出处
《中国药业》
CAS
2017年第6期49-51,共3页
China Pharmaceuticals
关键词
达比加群酯
华法林
非瓣膜性房颤
疗效
安全性
dabigatran
warfarin
nonvalvular atrial fibrillation
efficacy
safety
